Developer docs
API playgroundTry for free, no card

Search company profiles

OmicInsight

Full company profile

uuid003pvni

Namestring
OmicInsight
Legal namestring
OmicInsight Corporation
Websiteurl
omicinsight.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

OmicInsight Corporation is a privately held biotechnology company founded in 2024 and headquartered in Santa Clara, California (incorporated in Delaware). The company develops an AI-powered spatial omics platform branded as Esper, which combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver high-resolution, subcellular-level molecular analysis for biopharma research. The platform's claimed performance metrics — 60x oil-immersion resolution using only a 20x air lens, 250nm subcellular resolution across tissue areas, 5x greater gene detection sensitivity than competitors, and 50x-100x higher throughput than conventional high-resolution imaging methods — underpin a positioning around cost-efficient, high-fidelity spatial biology at scale.

The company serves global biopharma companies engaged in drug discovery, mechanism-of-action studies, and PK/PD research, as well as academic research institutions reached through its North American channel partnership with Psomagen. OmicInsight's revenue streams are spatial omics analysis services and platform access/licensing on subscription/recurring terms, with quote-based enterprise pricing rather than a published rate card. Go-to-market combines direct enterprise field sales to pharmaceutical companies with channel distribution through Psomagen, co-marketing with Gradiant Bioconvergence (GBCC) in the organoid vertical, and technology showcase events. In February 2026, OmicInsight unveiled Project Cortex, a Bio-Physical AI roadmap designed to integrate AI directly into laboratory hardware for autonomous experimental control and patient-specific assay design, with an active joint research collaboration with an unnamed top-tier global pharmaceutical firm.

Short descriptiontext

OmicInsight is a privately held biotechnology company developing the AI-powered Esper spatial omics platform, which combines proprietary Synthetic Aperture Optics with subcellular imaging to serve global biopharma companies and academic institutions in drug discovery research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSanta Clara, United States
HQ citystring
Santa Clara
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial omics analysis, multi-omics imaging, drug discovery platform, AI spatial biology, single-molecule imaging
Industry5 codes
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Optical Instruments & Lenses3827
Product category
Spatial Omics Analysis Platform
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Spatial Omics Analysis Services
TypeSubscription Recurring
Description

High-resolution spatial omics analysis services offered to biopharma companies for drug discovery, mechanism of action studies, and PK/PD research. Services include subcellular-level multi-omics analysis at scale.

indystar.com
2Platform Access and Licensing
TypeSubscription Recurring
Description

Access to the Esper Platform for high-resolution imaging and multi-omics analysis capabilities. Channel partnerships through Psomagen expanding commercial reach.

omicinsight.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Esper Platform
Description

Integrated platform combining gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology for high-fidelity spatial analysis, delivering unprecedented sensitivity and resolution at reduced cost. Features include 60x oil-immersion resolution using a 20x air lens, 250nm resolution across tissue areas, and AI-driven insights for drug discovery and precision medicine.

omicinsight.com
Core offering1 text field

OmicInsight develops and sells the Esper Platform, an AI-powered spatial omics analysis platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver subcellular-resolution molecular imaging, single-molecule sensitivity, and customizable AI-driven analysis pipelines for biopharma drug discovery and precision medicine. The company is developing Project Cortex, a Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for autonomous experimental control, and offers spatial omics analysis services to pharmaceutical companies and research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 5x greater gene detection sensitivity than current market competitors
+3 more records
Product overview1 text field

OmicInsight offers a unified platform architecture centered on the Esper Platform for spatial omics analysis. The platform integrates proprietary Synthetic Aperture Optics (SAO) technology enabling 60x oil-immersion resolution and 5x greater sensitivity than competitors. The company is developing Project Cortex, a Bio-Physical AI roadmap that extends the platform with autonomous laboratory capabilities. The product portfolio also includes associated SAO technology as the underlying optical innovation powering the platform's high-fidelity imaging capabilities.

Product and service3 records
1Esper Platform
CategoryCore spatial omics platform
Description

AI-powered spatial omics platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver unprecedented sensitivity and resolution for molecular analysis within biological tissues, enabling single-molecule detection, high-resolution imaging, and customizable analysis pipelines for drug discovery and precision medicine.

2Project Cortex (Bio-Physical AI Platform)
CategoryAutonomous laboratory AI platform
Description

Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for real-time autonomous experimental control, featuring industrial-scale high-fidelity data generation, self-optimizing adaptive experimental system, closed-loop feedback adjustment of laser power, flow speed, and reagent concentration, and AI-designed patient-specific diagnostic assays for precision medicine.

3Spatial Omics Analysis Services
CategoryAnalytical services
Description

High-resolution spatial omics analysis services offered to biopharma companies for drug discovery, mechanism of action studies, and PK/PD research, including subcellular-level multi-omics analysis at scale delivered to pharmaceutical enterprises and channel partner networks.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Top-tier global pharmaceutical firm (unnamed)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Joint research collaboration on Project Cortex Bio-Physical AI platform. The unnamed pharmaceutical firm is engaged in joint research to develop and validate the autonomous laboratory technology for drug discovery applications.

omicinsight.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-20
Description

Marketing agreement where Psomagen offers OmicInsight's high-resolution imaging and multi-omics analysis capabilities as part of Psomagen's spatial transcriptomics service portfolio. Psomagen, headquartered in Rockville, MD, is a premier North American provider of transcriptomic and genomic services with over 20 years of experience serving top-tier academic and pharmaceutical institutions. Acts as channel partner introducing OmicInsight's specialized services to their extensive client network including world-class research institutions and leading global pharmaceutical companies.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

Strategic co-marketing agreement to jointly advance research at the interface of spatial biology and organoid science. Partnership combines OmicInsight's high-sensitivity spatial transcriptomics platform with GBCC's next-generation organoid models to enable unprecedented clarity and accessibility for researchers. Anticipated platform to reshape drug discovery, precision medicine, and regenerative medicine. GBCC headquartered in Seoul, South Korea is an organoid-based platform company integrating PDO banking system with AI and genomics analytics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bio-Techne's RNAscope ISH technology is a long-established gold-standard spatial RNA platform serving pharma and academic customers, overlapping with OmicInsight's claims of gold-standard RNA FISH chemistry integration within Esper.

TypeDirect peer
Description

Resolve Biosciences offers Molecular Cartography spatial transcriptomics with subcellular resolution, targeting biopharma discovery and translational researchers with similar use cases to OmicInsight's Esper platform.

TypeDirect peer
Description

10x Genomics is the dominant spatial transcriptomics and single-cell omics platform company (Xenium, Visium HD, Chromium). It directly competes with OmicInsight's Esper platform for biopharma and academic research budgets targeting subcellular-resolution spatial omics.

TypeDirect peer
Description

Standard BioTools (formerly Fluidigm) provides Hyperion imaging mass cytometry for spatial proteomics. It serves the same biopharma biomarker discovery use cases with comparable per-tissue-area high-multiplex workflows.

TypeDirect peer
Description

Vizgen commercializes MERFISH-based spatial transcriptomics instruments for subcellular gene expression profiling. Vizgen competes directly with OmicInsight's Esper platform on subcellular-resolution spatial RNA analysis for pharma and academic researchers.

TypeDirect peer
Description

Akoya's PhenoCycler (CODEX) and OPAL multiplexed immunofluorescence platforms compete in the high-plex spatial proteomics and tissue imaging markets that OmicInsight targets with its Esper platform for biopharma biomarker discovery.

TypeDirect peer
Description

Bruker acquired NanoString's spatial biology business including CosMx SMI and GeoMx digital spatial profiling. CosMx is the closest head-to-head competitor to Esper in high-plex single-cell spatial RNA analysis for biopharma translational research.

TypeOthers
Description

Leica (Danaher) is a major microscopy and sample-prep instrument supplier feeding into spatial omics workflows. It is a complementary/adjacent provider of high-resolution optical instruments relevant to OmicInsight's SAO optics roadmap rather than a direct spatial omics competitor.

TypeOthers
Description

Abcam supplies antibody reagents widely used in spatial proteomics and immunohistochemistry workflows. As a complementary reagent/antibody provider, it enables OmicInsight's protein-RNA co-detection use cases without directly competing.

10Carl Zeiss Microscopy
TypeOthers
Description

ZEISS is a leading microscopy and optics manufacturer whose high-resolution objectives and imaging platforms underpin much of the spatial biology ecosystem. It is an adjacent optical-instrumentation vendor relevant to the SAO optics build-out.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OmicInsight

Spatial Omics Analysis Platformomicinsight.com

OmicInsight is a privately held biotechnology company developing the AI-powered Esper spatial omics platform, which combines proprietary Synthetic Aperture Optics with subcellular imaging to serve global biopharma companies and academic institutions in drug discovery research.

What OmicInsight does

OmicInsight Corporation is a privately held biotechnology company founded in 2024 and headquartered in Santa Clara, California (incorporated in Delaware). The company develops an AI-powered spatial omics platform branded as Esper, which combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver high-resolution, subcellular-level molecular analysis for biopharma research. The platform's claimed performance metrics — 60x oil-immersion resolution using only a 20x air lens, 250nm subcellular resolution across tissue areas, 5x greater gene detection sensitivity than competitors, and 50x-100x higher throughput than conventional high-resolution imaging methods — underpin a positioning around cost-efficient, high-fidelity spatial biology at scale.

The company serves global biopharma companies engaged in drug discovery, mechanism-of-action studies, and PK/PD research, as well as academic research institutions reached through its North American channel partnership with Psomagen. OmicInsight's revenue streams are spatial omics analysis services and platform access/licensing on subscription/recurring terms, with quote-based enterprise pricing rather than a published rate card. Go-to-market combines direct enterprise field sales to pharmaceutical companies with channel distribution through Psomagen, co-marketing with Gradiant Bioconvergence (GBCC) in the organoid vertical, and technology showcase events. In February 2026, OmicInsight unveiled Project Cortex, a Bio-Physical AI roadmap designed to integrate AI directly into laboratory hardware for autonomous experimental control and patient-specific assay design, with an active joint research collaboration with an unnamed top-tier global pharmaceutical firm.

OmicInsight firmographics

Firmographics
Name
OmicInsight
Legal name
OmicInsight Corporation
Website
https://omicinsight.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
OmicInsight is a privately held biotechnology company developing the AI-powered Esper spatial omics platform, which combines proprietary Synthetic Aperture Optics with subcellular imaging to serve global biopharma companies and academic institutions in drug discovery research.
Ownership category
akta.pro rank

OmicInsight industry classification

Industry
Product category
Spatial Omics Analysis Platform
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • Spatial omics analysis
  • Multi-omics imaging
  • Drug discovery platform
  • AI spatial biology
  • Single-molecule imaging

Where OmicInsight is headquartered

Location

Headquarters

HQ city
Santa Clara
HQ country
United States
HQ region
North America

Offices2 records

Markets served

OmicInsight business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Spatial Omics Analysis Services: High-resolution spatial omics analysis services offered to biopharma companies for drug discovery, mechanism of action studies, and PK/PD research. Services include subcellular-level multi-omics analysis at scale.
  2. Platform Access and Licensing: Access to the Esper Platform for high-resolution imaging and multi-omics analysis capabilities. Channel partnerships through Psomagen expanding commercial reach.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

OmicInsight product offering

Product offering

Core offering

OmicInsight develops and sells the Esper Platform, an AI-powered spatial omics analysis platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver subcellular-resolution molecular imaging, single-molecule sensitivity, and customizable AI-driven analysis pipelines for biopharma drug discovery and precision medicine. The company is developing Project Cortex, a Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for autonomous experimental control, and offers spatial omics analysis services to pharmaceutical companies and research institutions.

Product overview

OmicInsight offers a unified platform architecture centered on the Esper Platform for spatial omics analysis. The platform integrates proprietary Synthetic Aperture Optics (SAO) technology enabling 60x oil-immersion resolution and 5x greater sensitivity than competitors. The company is developing Project Cortex, a Bio-Physical AI roadmap that extends the platform with autonomous laboratory capabilities. The product portfolio also includes associated SAO technology as the underlying optical innovation powering the platform's high-fidelity imaging capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Esper Platform: Integrated platform combining gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology for high-fidelity spatial analysis, delivering unprecedented sensitivity and resolution at reduced cost. Features include 60x oil-immersion resolution using a 20x air lens, 250nm resolution across tissue areas, and AI-driven insights for drug discovery and precision medicine.

Products and services

  • Esper Platform AI-powered spatial omics platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver unprecedented sensitivity and resolution for molecular analysis within biological tissues, enabling single-molecule detection, high-resolution imaging, and customizable analysis pipelines for drug discovery and precision medicine.
  • Project Cortex (Bio-Physical AI Platform) Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for real-time autonomous experimental control, featuring industrial-scale high-fidelity data generation, self-optimizing adaptive experimental system, closed-loop feedback adjustment of laser power, flow speed, and reagent concentration, and AI-designed patient-specific diagnostic assays for precision medicine.
  • Spatial Omics Analysis Services High-resolution spatial omics analysis services offered to biopharma companies for drug discovery, mechanism of action studies, and PK/PD research, including subcellular-level multi-omics analysis at scale delivered to pharmaceutical enterprises and channel partner networks.

Quantifiable outcome

  • 5x greater gene detection sensitivity than current market competitors
  • +3 more outcomes

Companies that use OmicInsight

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

OmicInsight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature7 records

OmicInsight partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major.

  • Top-tier global pharmaceutical firm (unnamed)majorStrategic or Co-development Partner · 23 February 2026Joint research collaboration on Project Cortex Bio-Physical AI platform. The unnamed pharmaceutical firm is engaged in joint research to develop and validate the autonomous laboratory technology for drug discovery applications.
  • Psomagen, Inc.majorChannel Partner/ Reseller/ Distributor · 20 January 2026Marketing agreement where Psomagen offers OmicInsight's high-resolution imaging and multi-omics analysis capabilities as part of Psomagen's spatial transcriptomics service portfolio. Psomagen, headquartered in Rockville, MD, is a premier North American provider of transcriptomic and genomic services with over 20 years of experience serving top-tier academic and pharmaceutical institutions. Acts as channel partner introducing OmicInsight's specialized services to their extensive client network including world-class research institutions and leading global pharmaceutical companies.
  • Gradiant Bioconvergence (GBCC)majorStrategic or Co-development Partner · 29 October 2025Strategic co-marketing agreement to jointly advance research at the interface of spatial biology and organoid science. Partnership combines OmicInsight's high-sensitivity spatial transcriptomics platform with GBCC's next-generation organoid models to enable unprecedented clarity and accessibility for researchers. Anticipated platform to reshape drug discovery, precision medicine, and regenerative medicine. GBCC headquartered in Seoul, South Korea is an organoid-based platform company integrating PDO banking system with AI and genomics analytics.

Scale indicators7 records

Recent moves6 records

Expansion highlights8 records

OmicInsight competitors and assessment

Company assessment

Broad incumbents

  • Bio-Techne: Bio-Techne's RNAscope ISH technology is a long-established gold-standard spatial RNA platform serving pharma and academic customers, overlapping with OmicInsight's claims of gold-standard RNA FISH chemistry integration within Esper.

Direct peers

  • Resolve Biosciences: Resolve Biosciences offers Molecular Cartography spatial transcriptomics with subcellular resolution, targeting biopharma discovery and translational researchers with similar use cases to OmicInsight's Esper platform.
  • 10x Genomics: 10x Genomics is the dominant spatial transcriptomics and single-cell omics platform company (Xenium, Visium HD, Chromium). It directly competes with OmicInsight's Esper platform for biopharma and academic research budgets targeting subcellular-resolution spatial omics.
  • Standard BioTools: Standard BioTools (formerly Fluidigm) provides Hyperion imaging mass cytometry for spatial proteomics. It serves the same biopharma biomarker discovery use cases with comparable per-tissue-area high-multiplex workflows.
  • Vizgen: Vizgen commercializes MERFISH-based spatial transcriptomics instruments for subcellular gene expression profiling. Vizgen competes directly with OmicInsight's Esper platform on subcellular-resolution spatial RNA analysis for pharma and academic researchers.
  • Akoya Biosciences: Akoya's PhenoCycler (CODEX) and OPAL multiplexed immunofluorescence platforms compete in the high-plex spatial proteomics and tissue imaging markets that OmicInsight targets with its Esper platform for biopharma biomarker discovery.
  • Bruker Spatial Biology (formerly NanoString): Bruker acquired NanoString's spatial biology business including CosMx SMI and GeoMx digital spatial profiling. CosMx is the closest head-to-head competitor to Esper in high-plex single-cell spatial RNA analysis for biopharma translational research.

Others

  • Leica Microsystems: Leica (Danaher) is a major microscopy and sample-prep instrument supplier feeding into spatial omics workflows. It is a complementary/adjacent provider of high-resolution optical instruments relevant to OmicInsight's SAO optics roadmap rather than a direct spatial omics competitor.
  • Abcam (Danaher): Abcam supplies antibody reagents widely used in spatial proteomics and immunohistochemistry workflows. As a complementary reagent/antibody provider, it enables OmicInsight's protein-RNA co-detection use cases without directly competing.
  • Carl Zeiss Microscopy: ZEISS is a leading microscopy and optics manufacturer whose high-resolution objectives and imaging platforms underpin much of the spatial biology ecosystem. It is an adjacent optical-instrumentation vendor relevant to the SAO optics build-out.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

OmicInsight social profiles

Digital presence

OmicInsight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OmicInsight leadership team

Management profile

Number of profiles

Profiles3 records

OmicInsight funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OmicInsight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OmicInsight

What does OmicInsight do?

OmicInsight develops and sells the Esper Platform, an AI-powered spatial omics analysis platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver subcellular-resolution molecular imaging, single-molecule sensitivity, and customizable AI-driven analysis pipelines for biopharma drug discovery and precision medicine. The company is developing Project Cortex, a Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for autonomous experimental control, and offers spatial omics analysis services to pharmaceutical companies and research institutions.

Is OmicInsight a public or private company?

OmicInsight is a private company. It is classified as venture growth investor backed and is currently operating.

When was OmicInsight founded?

OmicInsight was founded in 2024. It employs 1 to 10 people.

Where is OmicInsight based?

OmicInsight is headquartered in Santa Clara, United States, in the North America region.

How does OmicInsight make money?

Two revenue lines are on record. Spatial Omics Analysis Services are the primary driver. The others are platform Access and Licensing.

Who are OmicInsight's main competitors?

Bio-Techne is listed as a broad incumbent. Direct peers are Resolve Biosciences, 10x Genomics, Standard BioTools, Vizgen, Akoya Biosciences and Bruker Spatial Biology (formerly NanoString). Others are Leica Microsystems, Abcam (Danaher) and Carl Zeiss Microscopy.

Does OmicInsight have an API?

No public API is recorded for OmicInsight.

What industry is OmicInsight in?

OmicInsight's product category is Spatial Omics Analysis Platform. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireOmicInsight Accelerates AI Transformation Roadmap with Strategic Leadership AppointmentsOmicInsight Corporation announced a strategic leadership realignment to accelerate its AI Transformation roadmap, appointing Eric Abel, Ph.D. as Vice President of Product Management & Strategy following the departure of Co-CEO Jae Won Kim. The restructuring consolidates leadership under CEO Josh Ryu, Ph.D. as the company enters a critical expansion phase aimed at driving global biopharma integration and establishing a new AI-native standard in drug discovery.EIN PresswireOmicInsight Unveils 'Cortex' - Bio-Physical AI Roadmap to Redefine the Future of Drug DiscoveryOmicInsight Corporation announced Project Cortex, a Bio-Physical AI platform designed to integrate artificial intelligence directly into laboratory hardware to automate and optimize biological research workflows, with plans for real-time autonomous experimental control. The platform claims to deliver five times greater gene detection sensitivity than current market competitors and is currently engaged in joint research with an unnamed top-tier global pharmaceutical firm. The company plans to host a technology showcase in Seoul on March 4, 2026, to present the platform's roadmap to research institutions, clinical partners, and institutional investors.Florida TodayLOTTE Holdings Healthcare and Biopharmaceutical CVC Announces Investment in OmicInsight CorporationLOTTE Holdings Co., Ltd. announced an investment in OmicInsight Corporation, a biotechnology company specializing in AI-driven spatial and multi-omics analysis for drug discovery and precision medicine. OmicInsight's proprietary Synthetic Aperture Optics platform enables 50x-100x higher throughput compared to conventional high-resolution imaging methods. The investment is expected to accelerate OmicInsight's business expansion, strengthen strategic partnerships in translational research, and support the company's entry into diagnostics.The Florida Times-UnionLOTTE Holdings Healthcare and Biopharmaceutical CVC Announces Investment in OmicInsight CorporationLOTTE Holdings announced an investment in OmicInsight Corporation, a biotechnology firm specializing in AI-driven spatial and multi-omics analysis, to support growth in drug discovery, diagnostics, and personalized medicine. The investment aims to accelerate OmicInsight’s development and expand its strategic partnerships in healthcare. The firms are based in Japan and the United States respectively.The Providence JournalLOTTE Holdings Healthcare and Biopharmaceutical CVC Announces Investment in OmicInsight CorporationLOTTE Holdings announced an investment in OmicInsight Corporation through its Healthcare and Biopharmaceutical CVC. OmicInsight, founded in 2024 and headquartered in Santa Clara, California, is a biotechnology company specializing in AI-driven spatial and multi-omics analysis using its proprietary Synthetic Aperture Optics platform Esper™. The investment aims to accelerate OmicInsight's business expansion into translational research, drug discovery partnerships, and diagnostics while leveraging LOTTE Holdings' global network.Hattiesburg AmericanLOTTE Holdings Healthcare and Biopharmaceutical CVC Announces Investment in OmicInsight CorporationLOTTE Holdings announced an investment in OmicInsight Corporation, a biotech company specializing in AI-driven spatial and multi-omics analysis, to support advancements in drug discovery and precision medicine. The investment aims to accelerate OmicInsight's business development, including partnerships, diagnostics, and AI/ML technology expansion. The event signifies a strategic move by LOTTE Holdings to boost healthcare innovation and expand OmicInsight’s market reach.Serrari GroupLOTTE Holdings Leads Strategic Investment in OmicInsight to Advance AI-Powered Multi-Omics Diagnostics in Precision Medicine » Serrari GroupOmicInsight Corporation, a Santa Clara-based biotechnology company specializing in AI-driven high-sensitivity spatial omics analysis, announced a significant strategic investment round led by LOTTE Holdings through its Healthcare & Biopharmaceutical Corporate Venture Capital arm, with participation from Adelphi Ventures. The capital injection is designed to accelerate OmicInsight's business roadmap, including expansion of AI-driven diagnostics and premium subcellular-level multi-omics analysis at scale for the pharmaceutical industry. The investment positions OmicInsight to leverage its proprietary spatial omics imaging technology and AI platform to capture market opportunity in the rapidly growing spatial biology sector, projected to reach $829.81 million by 2030.The Indianapolis StarOmicInsight Secures Strategic Investment Led by LOTTE Holdings to Accelerate AI-Powered Multi-Omics PlatformOmicInsight Corporation, a Santa Clara-based biotechnology company specializing in AI-driven spatial omics analysis, announced securing a strategic investment round led by LOTTE Holdings' Healthcare & Biopharmaceutical Corporate Venture Capital, with participation from existing investor Adelphi Ventures and a healthcare-focused private investment firm. The capital injection is earmarked to accelerate the company's business roadmap, including expansion of AI-driven diagnostics and subcellular-level multi-omics analysis at scale. OmicInsight aims to leverage this funding to expand partnerships in the biopharma industry and bring its high-resolution multi-omic data solutions to the forefront of global drug discovery.The Evening SunOmicInsight Secures Strategic Investment Led by LOTTE Holdings to Accelerate AI-Powered Multi-Omics PlatformOmicInsight Corporation, a Santa Clara-based biotechnology company specializing in AI-driven spatial omics analysis, announced securing a strategic investment round led by LOTTE Holdings' Healthcare & Biopharmaceutical Corporate Venture Capital, with participation from a healthcare-focused private investment firm and existing investor Adelphi Ventures. The capital will accelerate OmicInsight's business roadmap, including expansion of AI-driven diagnostics and subcellular-level multi-omics analysis at scale for pharmaceutical applications. The company aims to leverage its investors' global networks to expand its customer base and bring high-resolution multi-omic data solutions to the global drug discovery market.